Cidara Therapeutics Inc (NASDAQ:CDTX) Stock Sees Bullish Uptrend After The Recent News
Cidara Therapeutics Inc (NASDAQ:CDTX) jumped 10% and 16% for the week after announcing the completion of enrolment in the pivotal phase III ReSTORE study. The company is surveying in collaboration with Mundipharm, and it is evaluating rexafungin’s safety and efficacy as first-line invasive candidiasis and candidemia treatment. The study enrolled 184 invasive candidiasis and /or candidemia patients. This is a significant unmet need area for critically sick hospitalized patients and…